Eliem Therapeutics Stock Price To Book
| ELYMDelisted Stock | USD 3.04 0.04 1.30% |
Eliem Therapeutics fundamentals help investors to digest information that contributes to Eliem Therapeutics' financial success or failures. It also enables traders to predict the movement of Eliem Stock. The fundamental analysis module provides a way to measure Eliem Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eliem Therapeutics stock.
Eliem |
Eliem Therapeutics Company Price To Book Analysis
Eliem Therapeutics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Eliem Therapeutics Price To Book | 1.56 X |
Most of Eliem Therapeutics' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eliem Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, Eliem Therapeutics has a Price To Book of 1.5552 times. This is 93.94% lower than that of the Biotechnology sector and 74.25% lower than that of the Health Care industry. The price to book for all United States stocks is 83.65% higher than that of the company.
Eliem Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eliem Therapeutics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eliem Therapeutics could also be used in its relative valuation, which is a method of valuing Eliem Therapeutics by comparing valuation metrics of similar companies.Eliem Therapeutics is currently under evaluation in price to book category among its peers.
Eliem Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 122.66 M | |||
| Shares Outstanding | 67.06 M | |||
| Shares Owned By Insiders | 10.38 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 1.15 M | |||
| Price To Book | 1.56 X | |||
| EBITDA | (40.27 M) | |||
| Net Income | (35.12 M) | |||
| Cash And Equivalents | 122.95 M | |||
| Cash Per Share | 4.63 X | |||
| Total Debt | 349 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 17.48 X | |||
| Book Value Per Share | 3.33 X | |||
| Cash Flow From Operations | (20.6 M) | |||
| Short Ratio | 4.07 X | |||
| Earnings Per Share | (2.22) X | |||
| Target Price | 4.5 | |||
| Beta | -0.35 | |||
| Market Capitalization | 346.03 M | |||
| Total Asset | 110.47 M | |||
| Retained Earnings | (155.98 M) | |||
| Working Capital | 107.42 M | |||
| Net Asset | 110.47 M |
About Eliem Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eliem Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eliem Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eliem Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eliem Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |